Amova Asset Management Americas Inc. Lowers Stock Position in Standard BioTools Inc. $LAB

Amova Asset Management Americas Inc. reduced its stake in shares of Standard BioTools Inc. (NASDAQ:LAB) by 19.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,335,887 shares of the company’s stock after selling 1,055,942 shares during the period. Amova Asset Management Americas Inc.’s holdings in Standard BioTools were worth $5,507,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. M&T Bank Corp purchased a new position in shares of Standard BioTools during the 4th quarter valued at about $31,000. Russell Investments Group Ltd. lifted its position in shares of Standard BioTools by 2,989.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 25,021 shares of the company’s stock valued at $33,000 after buying an additional 24,211 shares in the last quarter. CIBC Asset Management Inc purchased a new position in shares of Standard BioTools during the 4th quarter valued at about $33,000. Federated Hermes Inc. lifted its position in shares of Standard BioTools by 103.6% during the 3rd quarter. Federated Hermes Inc. now owns 28,545 shares of the company’s stock valued at $37,000 after buying an additional 14,523 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its position in shares of Standard BioTools by 50.3% during the 2nd quarter. BNP Paribas Financial Markets now owns 29,826 shares of the company’s stock valued at $36,000 after buying an additional 9,986 shares in the last quarter. 53.74% of the stock is owned by hedge funds and other institutional investors.

Standard BioTools Trading Up 10.3%

NASDAQ LAB opened at $0.89 on Wednesday. The stock’s 50 day moving average is $0.98 and its 200 day moving average is $1.19. Standard BioTools Inc. has a 12 month low of $0.79 and a 12 month high of $1.72. The stock has a market cap of $345.95 million, a PE ratio of 4.43 and a beta of 1.39.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Wall Street Zen raised Standard BioTools from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings cut Standard BioTools from a “sell (d+)” rating to a “sell (d)” rating in a report on Wednesday, May 27th. Two research analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Standard BioTools currently has a consensus rating of “Reduce” and a consensus target price of $1.35.

Standard BioTools Company Profile

Standard BioTools, Inc (NASDAQ: LAB), formerly known as Fluidigm Corporation, is a life sciences tools company that develops and commercializes high-parameter, single-cell and spatial biology solutions. The company’s platforms integrate microfluidics, mass cytometry, sequencing and imaging to enable researchers to probe cellular heterogeneity, molecular interactions and complex tissue architecture. Its end users span academic institutions, pharmaceutical and biotechnology companies worldwide.

The company’s flagship products include mass cytometry systems—such as the Helios and Hyperion Imaging System—for multiplexed protein analysis at single-cell resolution, and the Chromium-style single-cell genomic tools for high-throughput gene expression profiling.